How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,338 results for

fluoroquinolones

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Out of Asia: the independent rise and global spread of fluoroquinolone-resistant Shigella Full Text available with Trip Pro

Out of Asia: the independent rise and global spread of fluoroquinolone-resistant Shigella Shigella are ranked among the most prevalent aetiologies of diarrhoeal disease worldwide, disproportionately affecting young children in developing countries and high-risk communities in developed settings. Antimicrobial treatment, most commonly with fluoroquinolones, is currently recommended for Shigella infections to alleviate symptoms and control disease transmission. Resistance to fluoroquinolones has (...) emerged in differing Shigella species (S. dysenteriae, flexneri and sonnei) since the turn of the 21st century, originating in endemic areas, and latterly spreading into non-endemic regions. Despite occurring independently, the emergence of fluoroquinolone resistance in these different Shigella species shares striking similarities regarding their epidemiology and resistance mechanisms. Here, we review and discuss the current epidemiology of fluoroquinolone-resistant Shigella species, particularly

2018 Microbial Genomics

162. Effects of Lysozyme on the Activity of Ionic of Fluoroquinolone Species Full Text available with Trip Pro

Effects of Lysozyme on the Activity of Ionic of Fluoroquinolone Species Fluoroquinolones (FQs) constitute an important class of biologically active broad-spectrum antibacterial drugs that are which are in contact with many biological fluids under different acidity conditions. We studied the reactivity of ciprofloxacin (Cpx) and levofloxacin (Lev) and their interaction with lysozyme (Lyz) at different pH values, using UV-visible absorption, fluorescence, infrared spectroscopies supported by DFT

2018 Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry

163. Interaction between rpsL and gyrA mutations affects the fitness and dual resistance of Mycobacterium tuberculosis clinical isolates against streptomycin and fluoroquinolones Full Text available with Trip Pro

Interaction between rpsL and gyrA mutations affects the fitness and dual resistance of Mycobacterium tuberculosis clinical isolates against streptomycin and fluoroquinolones The interaction between different drug-resistant mutations is important to the development of drug resistance and its evolution. In this study, we aimed to reveal the potential relationships between mutations conferring resistance to two important antituberculosis drugs streptomycin (STR) and fluoroquinolones (FLQ).We used

2018 Infection and drug resistance

164. Single-nucleotide polymorphisms related to fluoroquinolone and aminoglycoside resistance in Mycobacterium avium isolates Full Text available with Trip Pro

Single-nucleotide polymorphisms related to fluoroquinolone and aminoglycoside resistance in Mycobacterium avium isolates The relationships between fluoroquinolone and aminoglycoside resistance and single-nucleotide polymorphisms (SNPs) in gyrA, gyrB, and rpsL genes were investigated in 95 clinical isolates of Mycobacterium avium from China.Fluoroquinolone and aminoglycoside resistance were determined by the broth microdilution method. GyrA, gyrB, and rpsL were sequenced, SNPs were identified (...) , and the corresponding amino acid mutations were recorded.The M. avium isolates displayed high levels of ofloxacin (93.68%), ciprofloxacin (92.63%), and streptomycin (65.26%) resistance. Moxifloxacin (18.95%) and amikacin (2.11%) were highly active against the strains. Fluoroquinolone resistance involving gyrA and gyrB gene mutations was identified. For gyrA, the most frequent SNPs were T→C (71/95, 74.74%), followed by A→G (64/95, 67.37%) and T→C (62/95, 65.26%). The amino acid mutations occurred mainly

2018 Infection and drug resistance

165. Estimated Cardiac Risk Associated With Macrolides and Fluoroquinolones Decreases Substantially When Adjusting for Patient Characteristics and Comorbidities Full Text available with Trip Pro

Estimated Cardiac Risk Associated With Macrolides and Fluoroquinolones Decreases Substantially When Adjusting for Patient Characteristics and Comorbidities Some studies have found that antimicrobials, especially macrolides, increase the risk of cardiovascular death. We investigated potential cardiac-related events associated with antimicrobial use in a population of patients with acute myocardial infarction.For 185 010 Medicare beneficiaries, we recorded prescriptions for azithromycin (...) myocardial infarction, number of visits, and the influenza rate. In unadjusted analyses, macrolides and fluoroquinolones were associated with a risk of cardiac events. However, the risk associated with macrolide use was substantially attenuated after adjustment for a wide range of variables, and the risk associated with fluoroquinolones was no longer statistically significant. For example, for azithromycin, the odds ratio for any cardiac event or death was 1.35 (95% confidence interval, 1.27-1.44; P

2018 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

166. Tetracycline and fluoroquinolone resistance in clinical Ureaplasma spp. and Mycoplasma hominis isolates in France between 2010 and 2015. Full Text available with Trip Pro

Tetracycline and fluoroquinolone resistance in clinical Ureaplasma spp. and Mycoplasma hominis isolates in France between 2010 and 2015. As information on Ureaplasma spp. and Mycoplasma hominis resistance is currently limited, the aim of this study was to investigate the susceptibility of Ureaplasma spp. and M. hominis to tetracyclines and fluoroquinolones in France.The susceptibility of 1014 clinical isolates obtained in Bordeaux University Hospital (Bordeaux, France) between 2010 and 2015 (...) was evaluated using two commercial kits, S.I.R. Mycoplasma (Bio-Rad) from 1 January 2010 to 5 October 2012 and MYCOFAST RevolutioN kit (ELITech Group) from 6 October 2012 to 31 December 2015. The MICs of isolates designated as resistant were determined using the broth microdilution assay. Additionally, the tet(M) gene and fluoroquinolone resistance-associated mutations were identified.Among 831 Ureaplasma spp. isolates, the tetracycline, levofloxacin and moxifloxacin resistance rates were 7.5%, 1.2% and 0.1

2018 Journal of Antimicrobial Chemotherapy

167. <i>In vitro</i> Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents Against Human <i>Mycoplasmas</i> and <i>Ureaplasmas</i> Including Isolates with Defined Resistance Mechanisms. Full Text available with Trip Pro

In vitro Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents Against Human Mycoplasmas and Ureaplasmas Including Isolates with Defined Resistance Mechanisms. Levonadifloxacin (WCK 771) was evaluated against 68 type strains and clinical isolates of Mycoplasma genitalium, Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma spp. in comparison with moxifloxacin, levofloxacin, tetracycline, and azithromycin

2018 Antimicrobial Agents and Chemotherapy

168. Oral Fluoroquinolone and the Risk of Aortic Dissection. Full Text available with Trip Pro

Oral Fluoroquinolone and the Risk of Aortic Dissection. Previous studies raised safety concerns on the association between fluoroquinolone treatment and serious collagen disorders, aortic aneurysm and dissection (AA/AD).This study sought to evaluate this association via a case-crossover analysis in a large national administrative database.A case-crossover design was used to compare the distributions of fluoroquinolone exposure for the same patient across a 60-day period before the AA/AD event (...) AA/AD patients were identified between 2001 and 2011. In the main case-crossover analysis, exposure to fluoroquinolone was more frequent during the hazard periods than during the referent periods (1.6% vs. 0.6%; odds ratio [OR]: 2.71; 95% confidence interval [CI]: 1.14 to 6.46). In the sensitivity analysis, after adjustment for infections and co-medications, the risk remains significant (OR: 2.05; 95% CI: 1.13 to 3.71). An increased risk of AA/AD was observed for prolonged exposure

2018 Journal of the American College of Cardiology

169. Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients

Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients (PERFECT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our

2018 Clinical Trials

170. A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events

A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03479736 Recruitment Status : Completed First Posted : March 27, 2018 Last Update Posted : July 6, 2018 Sponsor: Janssen Research & Development, LLC Information

2018 Clinical Trials

171. Fluoroquinolone Associated Disability

Fluoroquinolone Associated Disability Fluoroquinolone Associated Disability - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Fluoroquinolone Associated Disability The safety and scientific validity (...) of this study is to: 1) describe drug utilization for Fluoroquinolone(FQ), Azithromycin (AZ) and Sulfamethoxazole/Trimethoprim(ST) in the entire Truven MarketScan Commercial Claims and Encounters database (CCAE) database, and specifically among individuals in the Health and Productivity Management (HPM) during the observation period; 2) describe the rate of disability associated with 2 or more System Organ Class adverse events (SOC AEs) and exposure to FQs for several acute, uncomplicated indications; and 3

2018 Clinical Trials

172. Outbreak of Fluoroquinolone-Resistant Campylobacter jejuni Infections Associated with Raw Milk Consumption from a Herdshare Dairy — Colorado, 2016 Full Text available with Trip Pro

Outbreak of Fluoroquinolone-Resistant Campylobacter jejuni Infections Associated with Raw Milk Consumption from a Herdshare Dairy — Colorado, 2016 In August 2016, a local public health agency (LPHA) notified the Colorado Department of Public Health and Environment (CDPHE) of two culture-confirmed cases of Campylobacter infection among persons who consumed raw (unpasteurized) milk from the same herdshare dairy. In Colorado, the sale of raw milk is illegal; however, herdshare programs, in which

2018 Morbidity and Mortality Weekly Report

173. Correction to: Prevalence and Quinolone Susceptibilities of Salmonella Isolated from the Feces of Preharvest Cattle Within Feedlots that Used a Fluoroquinolone to Treat Bovine Respiratory Disease, by Smith, A.B., Renter, D.G., Cernicchiaro, N., Shi, X., a Full Text available with Trip Pro

Correction to: Prevalence and Quinolone Susceptibilities of Salmonella Isolated from the Feces of Preharvest Cattle Within Feedlots that Used a Fluoroquinolone to Treat Bovine Respiratory Disease, by Smith, A.B., Renter, D.G., Cernicchiaro, N., Shi, X., a 29757694 2019 01 02 1556-7125 15 5 2018 05 Foodborne pathogens and disease Foodborne Pathog. Dis. Correction to: Prevalence and Quinolone Susceptibilities of Salmonella Isolated from the Feces of Preharvest Cattle Within Feedlots that Used (...) a Fluoroquinolone to Treat Bovine Respiratory Disease, by Smith, A.B., Renter, D.G., Cernicchiaro, N., Shi, X., and Nagaraja, T.G. Foodborne Path Dis 2016;6:303-308. DOI: 10.1089/fpd.2015.2081. 308 10.1089/fpd.2015.2081.correx eng Journal Article Published Erratum United States Foodborne Pathog Dis 101120121 1535-3141 Foodborne Pathog Dis. 2016 Jun;13(6):303-8 26990393 2018 5 15 6 0 2018 5 15 6 0 2018 5 15 6 1 ppublish 29757694 10.1089/fpd.2015.2081.correx PMC5963221

2018 Foodborne pathogens and disease

174. Patients at Risk for Aortic Rupture Often Exposed to Fluoroquinolones During Hospitalization. Full Text available with Trip Pro

Patients at Risk for Aortic Rupture Often Exposed to Fluoroquinolones During Hospitalization. Several studies have indicated that fluoroquinolone use may be associated with an increased risk of aortic aneurysm or dissection (AAD). Because patients with AAD or Marfan syndrome are at increased risk for aortic rupture, we performed a retrospective cohort study to determine the prevalence of systemic fluoroquinolone exposure and predictors of fluoroquinolone use in these patients. Data were (...) obtained from the advisory board billing and administrative database, which contained information on 22 million adult hospitalizations in the United States for the study period (2009 to 2015). International Classification of Diseases (9/10) and Current Procedural Terminology codes were used to identify patients who had AAD or Marfan syndrome or underwent aortic repair. We identified 136,789 admissions for AAD, which involved 99,818 unique patients, 20% of whom received fluoroquinolone during a hospital

2018 Antimicrobial Agents and Chemotherapy

175. Molecular Study of Quinolone Resistance Determining Regions of gyrA Gene and parC Genes in Clinical Isolates of Acintobacter baumannii Resistant to Fluoroquinolone Full Text available with Trip Pro

Molecular Study of Quinolone Resistance Determining Regions of gyrA Gene and parC Genes in Clinical Isolates of Acintobacter baumannii Resistant to Fluoroquinolone Acinetobacterb aumannii (A. baumannii) is an important pathogen in health care associated infections. Quinolone resistance has emerged in this pathogen.The aim of the present study was to determine the presence of mutations of gyrA gene and parC genes by Restriction Fragment Length Polymorphism Polymerase Chain Reaction (RFLP-PCR

2018 The open microbiology journal

176. Predictors of fluoroquinolone-resistant bacteria in the rectal vault of men undergoing prostate biopsy. (Abstract)

Predictors of fluoroquinolone-resistant bacteria in the rectal vault of men undergoing prostate biopsy. Fluoroquinolone (FQ)-resistant rectal vault flora is associated with infectious complications in men undergoing transrectal ultrasound-guided prostate needle biopsy (TRUS-PNB).To determine the patient factors that predict FQ-resistant rectal cultures in men who are undergoing transrectal ultrasound-guided prostate needle biopsy.An IRB approved retrospective review of 6183 consecutive men who

2018 Prostate cancer and prostatic diseases

177. Community Origins and Regional Differences Highlight Risk of Plasmid-Mediated Fluoroquinolone Resistant Enterobacteriaceae Infections in Children. Full Text available with Trip Pro

Community Origins and Regional Differences Highlight Risk of Plasmid-Mediated Fluoroquinolone Resistant Enterobacteriaceae Infections in Children. Fluoroquinolones (FQs) are uncommonly prescribed in children, yet pediatric multidrug-resistant (MDR)-Enterobacteriaceae (Ent) infections often reveal FQ resistance (FQR). We sought to define the molecular epidemiology of FQR and MDR-Ent in children.A case-control analysis of children with MDR-Ent infections at 3 Chicago hospitals was performed

2018 Pediatric Infectious Dsease Journal

178. Fluoroquinolone prophylaxis selects for meropenem non-susceptible Pseudomonas aeruginosa in patients with hematologic malignancies and hematopoietic-cell transplant recipients. Full Text available with Trip Pro

Fluoroquinolone prophylaxis selects for meropenem non-susceptible Pseudomonas aeruginosa in patients with hematologic malignancies and hematopoietic-cell transplant recipients. In Pseudomonas aeruginosa, fluoroquinolone exposure promotes resistance to carbapenems through up-regulation of efflux pumps and transcriptional down-regulation of the porin OprD. Evidence of this effect among hematologic malignancy (HM) patients or hematopoietic-cell transplant (HCT) recipients receiving fluoroquinolone (...) prophylaxis for neutropenia is lacking.We retrospectively evaluated episodes of P. aeruginosa bloodstream infections in HM patients or HCT recipients over a 7-year period at our institution. The association of fluoroquinolone prophylaxis at the time of infection with meropenem susceptibility of P. aeruginosa breakthrough isolates and risk factors for meropenem non-susceptibility were determined. Whole genome sequencing (WGS) and phenotypic assessment of meropenem efflux pump activity were performed

2018 Clinical Infectious Diseases

179. Hypersensitivity to fluoroquinolones: The expression of basophil activation markers depends on the clinical entity and the culprit fluoroquinolone. Full Text available with Trip Pro

Hypersensitivity to fluoroquinolones: The expression of basophil activation markers depends on the clinical entity and the culprit fluoroquinolone. Although fluoroquinolones (FQs) are generally well-tolerated antibiotics, increasing numbers of hypersensitivity reactions have been reported. These can be evaluated in vitro by basophil activation tests (BATs); however, sensitivity is not optimal. Many factors could influence sensitivity such as basophil activation markers. The objective

2016 Medicine

180. Fluoroquinolone antibiotic-induced joint and cartilage damage in children: a meta-analysis

Fluoroquinolone antibiotic-induced joint and cartilage damage in children: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>